GlaxoSmithKline and Merck: private-sector collaboration for the elimination of lymphatic filariasis.
Identifieur interne : 002C51 ( PubMed/Checkpoint ); précédent : 002C50; suivant : 002C52GlaxoSmithKline and Merck: private-sector collaboration for the elimination of lymphatic filariasis.
Auteurs : K M Gustavsen [États-Unis] ; M H Bradley ; A L WrightSource :
- Annals of tropical medicine and parasitology [ 1364-8594 ] ; 2009.
Descripteurs français
- KwdFr :
- Albendazole (ressources et distribution), Albendazole (usage thérapeutique), Filaricides (ressources et distribution), Filaricides (usage thérapeutique), Filariose lymphatique (), Filariose lymphatique (traitement médicamenteux), Filariose lymphatique (économie), Humains, Industrie pharmaceutique, Ivermectine (ressources et distribution), Ivermectine (usage thérapeutique), Santé mondiale, Secteur privé, Évaluation de programme.
- MESH :
- ressources et distribution : Albendazole, Filaricides, Ivermectine.
- traitement médicamenteux : Filariose lymphatique.
- usage thérapeutique : Albendazole, Filaricides, Ivermectine.
- économie : Filariose lymphatique.
- Filariose lymphatique, Humains, Industrie pharmaceutique, Santé mondiale, Secteur privé, Évaluation de programme.
English descriptors
- KwdEn :
- Albendazole (supply & distribution), Albendazole (therapeutic use), Drug Industry, Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (economics), Elephantiasis, Filarial (prevention & control), Filaricides (supply & distribution), Filaricides (therapeutic use), Global Health, Humans, Ivermectin (supply & distribution), Ivermectin (therapeutic use), Private Sector, Program Evaluation.
- MESH :
- chemical , supply & distribution : Albendazole, Filaricides, Ivermectin.
- chemical , therapeutic use : Albendazole, Filaricides, Ivermectin.
- drug therapy : Elephantiasis, Filarial.
- economics : Elephantiasis, Filarial.
- prevention & control : Elephantiasis, Filarial.
- Drug Industry, Global Health, Humans, Private Sector, Program Evaluation.
Abstract
More than 1000 million people in 82 countries are at risk of contracting the tropical disease lymphatic filariasis (LF). Although the disease is wide-spread, transmission of the causative parasites can be stopped through mass drug administrations based on a combination of anti-parasitic medicines. For more than 10 years, the pharmaceutical companies GlaxoSmithKline (GSK) and Merck & Co., Inc., have participated in a unique private-sector collaboration to support the global efforts to eliminate LF, through donations of drugs to prevent the disease. GSK's albendazole and Merck's ivermectin (Mectizan) now reach hundreds of millions of people each year, through national LF-elimination programmes carried out in collaboration with Ministries of Health, the World Health Organization, non-governmental organizations and local communities. Working in support of the Global Programme to Eliminate Lymphatic Filariasis, GSK and Merck not only provide donated medicines but also offer financial, programmatic and management expertise to support LF-elimination efforts worldwide.
DOI: 10.1179/000349809X12502035776478
PubMed: 19843393
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:19843393Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">GlaxoSmithKline and Merck: private-sector collaboration for the elimination of lymphatic filariasis.</title>
<author><name sortKey="Gustavsen, K M" sort="Gustavsen, K M" uniqKey="Gustavsen K" first="K M" last="Gustavsen">K M Gustavsen</name>
<affiliation wicri:level="2"><nlm:affiliation>Global Public Policy and Corporate Responsibility, Merck & Co., Inc, One Merck Drive, PO Box 100, WS 2A-56, Whitehouse Station, NJ 08889-0100, USA. ken_gustavsen@merck.com</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Global Public Policy and Corporate Responsibility, Merck & Co., Inc, One Merck Drive, PO Box 100, WS 2A-56, Whitehouse Station, NJ 08889-0100</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bradley, M H" sort="Bradley, M H" uniqKey="Bradley M" first="M H" last="Bradley">M H Bradley</name>
</author>
<author><name sortKey="Wright, A L" sort="Wright, A L" uniqKey="Wright A" first="A L" last="Wright">A L Wright</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2009">2009</date>
<idno type="RBID">pubmed:19843393</idno>
<idno type="pmid">19843393</idno>
<idno type="doi">10.1179/000349809X12502035776478</idno>
<idno type="wicri:Area/PubMed/Corpus">002C88</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002C88</idno>
<idno type="wicri:Area/PubMed/Curation">002C88</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002C88</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002C88</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002C88</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">GlaxoSmithKline and Merck: private-sector collaboration for the elimination of lymphatic filariasis.</title>
<author><name sortKey="Gustavsen, K M" sort="Gustavsen, K M" uniqKey="Gustavsen K" first="K M" last="Gustavsen">K M Gustavsen</name>
<affiliation wicri:level="2"><nlm:affiliation>Global Public Policy and Corporate Responsibility, Merck & Co., Inc, One Merck Drive, PO Box 100, WS 2A-56, Whitehouse Station, NJ 08889-0100, USA. ken_gustavsen@merck.com</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Global Public Policy and Corporate Responsibility, Merck & Co., Inc, One Merck Drive, PO Box 100, WS 2A-56, Whitehouse Station, NJ 08889-0100</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bradley, M H" sort="Bradley, M H" uniqKey="Bradley M" first="M H" last="Bradley">M H Bradley</name>
</author>
<author><name sortKey="Wright, A L" sort="Wright, A L" uniqKey="Wright A" first="A L" last="Wright">A L Wright</name>
</author>
</analytic>
<series><title level="j">Annals of tropical medicine and parasitology</title>
<idno type="eISSN">1364-8594</idno>
<imprint><date when="2009" type="published">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Albendazole (supply & distribution)</term>
<term>Albendazole (therapeutic use)</term>
<term>Drug Industry</term>
<term>Elephantiasis, Filarial (drug therapy)</term>
<term>Elephantiasis, Filarial (economics)</term>
<term>Elephantiasis, Filarial (prevention & control)</term>
<term>Filaricides (supply & distribution)</term>
<term>Filaricides (therapeutic use)</term>
<term>Global Health</term>
<term>Humans</term>
<term>Ivermectin (supply & distribution)</term>
<term>Ivermectin (therapeutic use)</term>
<term>Private Sector</term>
<term>Program Evaluation</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Albendazole (ressources et distribution)</term>
<term>Albendazole (usage thérapeutique)</term>
<term>Filaricides (ressources et distribution)</term>
<term>Filaricides (usage thérapeutique)</term>
<term>Filariose lymphatique ()</term>
<term>Filariose lymphatique (traitement médicamenteux)</term>
<term>Filariose lymphatique (économie)</term>
<term>Humains</term>
<term>Industrie pharmaceutique</term>
<term>Ivermectine (ressources et distribution)</term>
<term>Ivermectine (usage thérapeutique)</term>
<term>Santé mondiale</term>
<term>Secteur privé</term>
<term>Évaluation de programme</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="supply & distribution" xml:lang="en"><term>Albendazole</term>
<term>Filaricides</term>
<term>Ivermectin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term>
<term>Filaricides</term>
<term>Ivermectin</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" qualifier="ressources et distribution" xml:lang="fr"><term>Albendazole</term>
<term>Filaricides</term>
<term>Ivermectine</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Albendazole</term>
<term>Filaricides</term>
<term>Ivermectine</term>
</keywords>
<keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Filariose lymphatique</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Drug Industry</term>
<term>Global Health</term>
<term>Humans</term>
<term>Private Sector</term>
<term>Program Evaluation</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Filariose lymphatique</term>
<term>Humains</term>
<term>Industrie pharmaceutique</term>
<term>Santé mondiale</term>
<term>Secteur privé</term>
<term>Évaluation de programme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">More than 1000 million people in 82 countries are at risk of contracting the tropical disease lymphatic filariasis (LF). Although the disease is wide-spread, transmission of the causative parasites can be stopped through mass drug administrations based on a combination of anti-parasitic medicines. For more than 10 years, the pharmaceutical companies GlaxoSmithKline (GSK) and Merck & Co., Inc., have participated in a unique private-sector collaboration to support the global efforts to eliminate LF, through donations of drugs to prevent the disease. GSK's albendazole and Merck's ivermectin (Mectizan) now reach hundreds of millions of people each year, through national LF-elimination programmes carried out in collaboration with Ministries of Health, the World Health Organization, non-governmental organizations and local communities. Working in support of the Global Programme to Eliminate Lymphatic Filariasis, GSK and Merck not only provide donated medicines but also offer financial, programmatic and management expertise to support LF-elimination efforts worldwide.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19843393</PMID>
<DateCreated><Year>2009</Year>
<Month>10</Month>
<Day>21</Day>
</DateCreated>
<DateCompleted><Year>2010</Year>
<Month>04</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised><Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1364-8594</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>103 Suppl 1</Volume>
<PubDate><Year>2009</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Annals of tropical medicine and parasitology</Title>
<ISOAbbreviation>Ann Trop Med Parasitol</ISOAbbreviation>
</Journal>
<ArticleTitle>GlaxoSmithKline and Merck: private-sector collaboration for the elimination of lymphatic filariasis.</ArticleTitle>
<Pagination><MedlinePgn>S11-5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1179/000349809X12502035776478</ELocationID>
<Abstract><AbstractText>More than 1000 million people in 82 countries are at risk of contracting the tropical disease lymphatic filariasis (LF). Although the disease is wide-spread, transmission of the causative parasites can be stopped through mass drug administrations based on a combination of anti-parasitic medicines. For more than 10 years, the pharmaceutical companies GlaxoSmithKline (GSK) and Merck & Co., Inc., have participated in a unique private-sector collaboration to support the global efforts to eliminate LF, through donations of drugs to prevent the disease. GSK's albendazole and Merck's ivermectin (Mectizan) now reach hundreds of millions of people each year, through national LF-elimination programmes carried out in collaboration with Ministries of Health, the World Health Organization, non-governmental organizations and local communities. Working in support of the Global Programme to Eliminate Lymphatic Filariasis, GSK and Merck not only provide donated medicines but also offer financial, programmatic and management expertise to support LF-elimination efforts worldwide.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gustavsen</LastName>
<ForeName>K M</ForeName>
<Initials>KM</Initials>
<AffiliationInfo><Affiliation>Global Public Policy and Corporate Responsibility, Merck & Co., Inc, One Merck Drive, PO Box 100, WS 2A-56, Whitehouse Station, NJ 08889-0100, USA. ken_gustavsen@merck.com</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bradley</LastName>
<ForeName>M H</ForeName>
<Initials>MH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wright</LastName>
<ForeName>A L</ForeName>
<Initials>AL</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Ann Trop Med Parasitol</MedlineTA>
<NlmUniqueID>2985178R</NlmUniqueID>
<ISSNLinking>0003-4983</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005369">Filaricides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>70288-86-7</RegistryNumber>
<NameOfSubstance UI="D007559">Ivermectin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>F4216019LN</RegistryNumber>
<NameOfSubstance UI="D015766">Albendazole</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D015766" MajorTopicYN="N">Albendazole</DescriptorName>
<QualifierName UI="Q000600" MajorTopicYN="N">supply & distribution</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004345" MajorTopicYN="N">Drug Industry</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005369" MajorTopicYN="N">Filaricides</DescriptorName>
<QualifierName UI="Q000600" MajorTopicYN="N">supply & distribution</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007559" MajorTopicYN="N">Ivermectin</DescriptorName>
<QualifierName UI="Q000600" MajorTopicYN="N">supply & distribution</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017149" MajorTopicYN="N">Private Sector</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015397" MajorTopicYN="N">Program Evaluation</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year>
<Month>10</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2009</Year>
<Month>11</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2010</Year>
<Month>4</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">19843393</ArticleId>
<ArticleId IdType="doi">10.1179/000349809X12502035776478</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>New Jersey</li>
</region>
</list>
<tree><noCountry><name sortKey="Bradley, M H" sort="Bradley, M H" uniqKey="Bradley M" first="M H" last="Bradley">M H Bradley</name>
<name sortKey="Wright, A L" sort="Wright, A L" uniqKey="Wright A" first="A L" last="Wright">A L Wright</name>
</noCountry>
<country name="États-Unis"><region name="New Jersey"><name sortKey="Gustavsen, K M" sort="Gustavsen, K M" uniqKey="Gustavsen K" first="K M" last="Gustavsen">K M Gustavsen</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C51 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002C51 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:19843393 |texte= GlaxoSmithKline and Merck: private-sector collaboration for the elimination of lymphatic filariasis. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:19843393" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
This area was generated with Dilib version V0.6.31. |